Altimmune financials
$2.97+0.34%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $41.0K | $20.0K | $426.0K | -$68.0K | $4.4M | $8.2M | $5.8M | $10.3M | $10.7M |
| Gross profit | $41.0K | $20.0K | $426.0K | -$68.0K | $4.4M | $8.2M | $5.8M | $10.3M | $10.7M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$94.5M | -$103.2M | -$95.9M | -$87.7M | -$96.9M | -$54.8M | -$21.5M | -$42.8M | -$52.0M |
| Net income | -$88.1M | -$95.1M | -$88.4M | -$84.7M | -$97.1M | -$49.0M | -$21.0M | -$42.5M | -$51.4M |
| Net margin | −214861.0% | −475295.0% | −20762.2% | 124577.9% | −2201.6% | −599.2% | −361.5% | −411.2% | −478.2% |
| Diluted EPS | $-1.00 | $-1.34 | $-1.66 | $-1.81 | $-2.35 | $-1.91 | $-1.60 | $-15.16 | $-118.91 |
| EBITDA | -$94.4M | -$102.9M | -$83.0M | -$87.2M | -$85.0M | -$54.4M | -$20.1M | -$17.6M | -$16.0M |
| Operating cash flow | -$67.5M | -$79.8M | -$75.8M | -$62.7M | -$78.9M | -$50.6M | -$9.6M | -$9.4M | -$20.2M |
| Free cash flow | -$67.5M | -$79.8M | -$75.9M | -$62.8M | -$91.1M | -$50.8M | -$9.6M | -$10.4M | -$20.3M |
| Diluted shares | 88.1M | 71.0M | 53.2M | 46.9M | 41.3M | 25.6M | 13.1M | 2.8M | 0.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $43.8M | $36.9M | $135.1M | $111.1M | $190.3M | $115.9M |
| Short-term investments | $229.7M | $95.0M | $62.7M | $73.8M | — | $100.0M |
| Total debt | $34.3M | $0.00 | $0.00 | $0.00 | $1.5M | $1.8M |
| Total assets | $279.9M | $139.3M | $210.6M | $206.9M | $218.9M | $245.1M |
| Total liabilities | $55.0M | $15.8M | $16.5M | $21.6M | $19.7M | $19.2M |
| Shareholders' equity | $224.9M | $123.5M | $194.1M | $185.3M | $199.1M | $225.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology